Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Synthetic Biologics Inc (NYSE MKT LLC:SYN)

2.11
Delayed Data
As of 10:19am ET
 -0.04 / -1.86%
Today’s Change
0.93
Today|||52-Week Range
4.32
-7.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$197.1M

Company Description

Synthetic Biologics, Inc. is a clinical stage company, which develops therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Its products portfolio includes SYN-004 and SYN-010. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Contact Information

Synthetic Biologics, Inc.
9605 Medical Center Drive
Rockville Maryland 20850
P:(301) 417-4367
Investor Relations:

Employees

Shareholders

Mutual fund holders4.27%
Individual stakeholders18.75%
Other institutional17.08%

Top Executives

Jeffrey Lucero RileyPresident, Chief Executive Officer & Director
Steven A. ShallcrossChief Financial Officer, Secretary & Treasurer
Michael KalekoSenior Vice President-Research & Development
Joseph SlimanSenior VP-Clinical & Regulatory Affairs
Deb MathewsVice President-Medical Affairs